Osmind

Osmind is a leading platform dedicated to empowering clinicians and researchers in their pursuit of innovative and life-saving mental health treatments. Recognizing the global impact of mental health disorders, particularly among young adults and their correlation with reduced lifespans, Osmind is at the forefront of accelerating scientific advancements in the field. Despite progress since the first FDA-approved psychiatric medication in 1954, a growing consensus among clinicians, patients, and researchers underscores the urgent need for novel approaches.

The Osmind treatment platform stands out as a unique solution tailored to address the specific challenges encountered by neuropsychiatric clinics, encompassing both general and interventional psychiatry, including treatments like transcranial magnetic stimulation, ketamine, SPRAVATO®, psychedelic medicine, and electroconvulsive therapy. Its core electronic health record (EHR) technology is meticulously designed for interventional treatment workflows, fostering a strong therapeutic alliance through journaling tools and facilitating health plan reimbursement, thereby overcoming a significant barrier to access for countless patients.

Osmind's platform is already contributing to the establishment of new benchmarks in mental health interventions. A collaborative effort with Stanford University School of Medicine resulted in the largest published real-world analysis of ketamine infusion therapy for depression, featured in the Journal of Affective Disorders (March 2022). Leveraging proprietary real-world data, Osmind is conducting multiple ongoing research studies, including an extensive ketamine analysis employing machine learning to forecast treatment outcomes.

Based in San Francisco, Osmind operates as a public benefit corporation, guided by a team of scientists, technologists, and psychiatrists. The company is supported by prominent investors, including DFJ Growth, General Catalyst, Future Ventures, Tiger Global, and Y Combinator.